Jubilant Ingrevia Ltd.
JUBLINGREACommodities filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
28 transcript(s)/analyst meet(s) served; 11 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 28 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| COVER_LETTER | 20220518 | 2022-03-31 | no | |
| TRANSCRIPT | 20220521 | 2022-03-31 | yes | |
| COVER_LETTER | 20220806 | 2022-06-30 | no | |
| TRANSCRIPT | 20220810 | 2022-06-30 | yes | |
| COVER_LETTER | 20221020 | 2022-09-30 | no | |
| TRANSCRIPT | 20221028 | 2022-09-30 | yes | |
| COVER_LETTER | 20230131 | 2022-12-31 | no | |
| TRANSCRIPT | 20230204 | 2022-12-31 | yes | |
| COVER_LETTER | 20230516 | 2023-03-31 | no | |
| TRANSCRIPT | 20230522 | 2023-03-31 | yes | |
| COVER_LETTER | 20230727 | 2023-06-30 | no | |
| TRANSCRIPT | 20230731 | 2023-06-30 | yes | |
| COVER_LETTER | 20231101 | 2023-09-30 | no | |
| TRANSCRIPT | 20231106 | 2023-09-30 | yes | |
| COVER_LETTER | 20240130 | 2023-12-31 | no | |
| TRANSCRIPT | 20240202 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240520 | 2024-03-31 | yes | |
| COVER_LETTER | 20240719 | 2024-06-30 | no | |
| TRANSCRIPT | 20241028 | 2024-09-30 | yes | |
| COVER_LETTER | 20250203 | 2024-12-31 | no | |
| TRANSCRIPT | 20250306 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250518 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250806 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251031 | 2025-09-30 | yes | |
| COVER_LETTER | 20260205 | 2025-12-31 | no | |
| TRANSCRIPT | 20260209 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260529 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260727 | 2026-06-30 | yes |
JUBLINGREA
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 635.35 |
| 52-week range | 541.3 – 763.8 |
| Return 1M | -10.11% |
| Return 3M | 2.2% |
| Return 1Y | -4.13% |
| Return 3Y | 36.87% |
| Return 5Y | -16.73% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 1,300.00 |
| Other income | 10.00 |
| Total income | 1,310.00 |
| Cost of materials consumed | 718.00 |
| Purchases of stock-in-trade | 64.00 |
| Changes in inventories | -153.00 |
| Employee benefit expense | 117.00 |
| Finance costs | 17.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.45 | 0.00 |
| institutions foreign | 0.06 | 0.00 |
| institutions domestic | 0.25 | 0.00 |
| mutual funds | 0.22 | 0.00 |
| public | 0.54 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| COVER_LETTER | 2025-12-31 | 11 |
| TRANSCRIPT | 2026-06-30 | 17 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,304.00 | 1,158.00 | 1,145.00 | 1,075.00 | 1,020.00 | 966.00 | 1,074.00 | 1,024.00 | 1,045.00 | 1,057.00 | 1,051.00 | 1,038.00 | 1,121.00 | 1,051.00 | 1,179.00 | 1,300.00 |
| Other income | 7.00 | 7.00 | 9.00 | 8.00 | 9.00 | 9.00 | 10.00 | 10.00 | 10.00 | 9.00 | 8.00 | 11.00 | 11.00 | 9.00 | 9.00 | 10.00 |
| Total income | 1,311.00 | 1,165.00 | 1,154.00 | 1,084.00 | 1,028.00 | 975.00 | 1,084.00 | 1,034.00 | 1,056.00 | 1,066.00 | 1,060.00 | 1,049.00 | 1,132.00 | 1,060.00 | 1,188.00 | 1,310.00 |
| Cost of materials consumed | 702.00 | 617.00 | 545.00 | 579.00 | 473.00 | 501.00 | 488.00 | 532.00 | 512.00 | 525.00 | 481.00 | 449.00 | 548.00 | 510.00 | 597.00 | 718.00 |
| Purchases of stock-in-trade | 37.00 | 33.00 | 54.00 | 21.00 | 14.00 | 18.00 | 13.00 | 7.00 | 8.00 | 9.00 | 32.00 | 32.00 | 31.00 | 42.00 | 44.00 | 64.00 |
| Changes in inventories | -24.00 | -40.00 | 49.00 | -50.00 | 18.00 | -11.00 | 95.00 | -11.00 | -13.00 | 4.00 | 20.00 | 38.00 | 22.00 | 4.00 | -23.00 | -153.00 |
| Employee benefit expense | 93.00 | 82.00 | 86.00 | 93.00 | 103.00 | 101.00 | 86.00 | 102.00 | 113.00 | 105.00 | 96.00 | 108.00 | 108.00 | 104.00 | 106.00 | 117.00 |
| Finance costs | 5.00 | 7.00 | 6.00 | 11.00 | 13.00 | 15.00 | 14.00 | 14.00 | 15.00 | 12.00 | 14.00 | 13.00 | 12.00 | 12.00 | 12.00 | 17.00 |
| Depreciation and amortisation | 31.00 | 30.00 | 30.00 | 32.00 | 34.00 | 34.00 | 36.00 | 39.00 | 40.00 | 40.00 | 39.00 | 41.00 | 41.00 | 45.00 | 48.00 | 51.00 |
| Other expenses | 343.00 | 315.00 | 309.00 | 315.00 | 294.00 | 261.00 | 301.00 | 285.00 | 301.00 | 275.00 | 276.00 | 268.00 | 277.00 | 265.00 | 291.00 | 355.00 |
| Total expenses | 1,187.00 | 1,044.00 | 1,078.00 | 1,002.00 | 949.00 | 920.00 | 1,033.00 | 968.00 | 975.00 | 971.00 | 958.00 | 949.00 | 1,039.00 | 982.00 | 1,076.00 | 1,170.00 |
| Profit before exceptional items and tax | 124.00 | 122.00 | 76.00 | 81.00 | 80.00 | 55.00 | 51.00 | 66.00 | 80.00 | 96.00 | 102.00 | 100.00 | 93.00 | 78.00 | 112.00 | 141.00 |
| Exceptional items | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -13.00 | 0.00 | 0.00 |
| Profit before tax | 124.00 | 122.00 | 76.00 | 81.00 | 80.00 | 55.00 | 51.00 | 66.00 | 80.00 | 96.00 | 102.00 | 100.00 | 93.00 | 65.00 | 112.00 | 141.00 |
| Current tax | 23.00 | 10.00 | 12.00 | 17.00 | 13.00 | 12.00 | 22.00 | 12.00 | 25.00 | 22.00 | 25.00 | 23.00 | 15.00 | 18.00 | 27.00 | 43.00 |
| Deferred tax | 16.00 | 20.00 | 12.00 | 7.00 | 10.00 | 5.00 | -0.00 | 5.00 | -4.00 | 4.00 | 2.00 | 2.00 | 8.00 | 0.00 | -2.00 | -8.00 |
| Tax expense | 40.00 | 30.00 | 23.00 | 24.00 | 22.00 | 17.00 | 22.00 | 17.00 | 21.00 | 26.00 | 28.00 | 25.00 | 23.00 | 19.00 | 25.00 | 35.00 |
| Profit for the period | 84.00 | 92.00 | 52.00 | 58.00 | 57.00 | 39.00 | 29.00 | 49.00 | 59.00 | 69.00 | 74.00 | 75.00 | 69.00 | 47.00 | 86.00 | 106.00 |
| Profit attributable to owners | 84.00 | 92.00 | 52.00 | 58.00 | 57.00 | 39.00 | 29.00 | 49.00 | 59.00 | 69.00 | 74.00 | 75.00 | 69.00 | 47.00 | 86.00 | 106.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | 0.00 | 1.00 | 3.00 | -0.00 | -0.00 | 1.00 | 3.00 | 2.00 | 2.00 | -7.00 | 6.00 | 10.00 | 7.00 | 1.00 | 2.00 | 5.00 |
| Total comprehensive income | 84.00 | 93.00 | 55.00 | 57.00 | 57.00 | 39.00 | 33.00 | 50.00 | 61.00 | 62.00 | 80.00 | 85.00 | 77.00 | 48.00 | 89.00 | 111.00 |
| Earnings per share, basic | 5.31 | 5.75 | 3.29 | 3.63 | 3.64 | 2.44 | 1.85 | 3.08 | 3.73 | 4.39 | 4.69 | 4.75 | 4.40 | 2.97 | 5.47 | 6.70 |
| Earnings per share, diluted | 5.30 | 5.75 | 3.29 | 3.63 | 3.64 | 2.43 | 1.85 | 3.08 | 3.73 | 4.39 | 4.64 | 4.75 | 4.40 | 2.97 | 5.39 | 6.68 |
Annual results, as filed
| Line | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|
| Revenue from operations | 684.00 | 4,949.00 | 4,773.00 | 4,136.00 | 4,178.00 | 4,388.00 |
| Other income | 3.00 | 31.00 | 33.00 | 35.00 | 38.00 | 41.00 |
| Total income | 687.00 | 4,981.00 | 4,806.00 | 4,171.00 | 4,215.00 | 4,429.00 |
| Cost of materials consumed | 363.00 | 2,798.00 | 2,548.00 | 2,040.00 | 2,050.00 | 2,105.00 |
| Purchases of stock-in-trade | 16.00 | 141.00 | 162.00 | 49.00 | 57.00 | 149.00 |
| Changes in inventories | -10.00 | -145.00 | -128.00 | 53.00 | 0.00 | 41.00 |
| Employee benefit expense | 49.00 | 327.00 | 343.00 | 384.00 | 418.00 | 426.00 |
| Finance costs | 7.00 | 31.00 | 22.00 | 53.00 | 56.00 | 49.00 |
| Depreciation and amortisation | 22.00 | 123.00 | 122.00 | 136.00 | 158.00 | 175.00 |
| Other expenses | 148.00 | 996.00 | 1,300.00 | 1,188.00 | 1,133.00 | 1,101.00 |
| Total expenses | 596.00 | 4,272.00 | 4,369.00 | 3,904.00 | 3,872.00 | 4,046.00 |
| Profit before exceptional items and tax | 90.00 | 709.00 | 437.00 | 268.00 | 344.00 | 383.00 |
| Exceptional items | -13.00 | 0.00 | -0.00 | 0.00 | 0.00 | -13.00 |
| Profit before tax | 77.00 | 709.00 | 437.00 | 268.00 | 344.00 | 370.00 |
| Current tax | 13.00 | 125.00 | 70.00 | 64.00 | 85.00 | 84.00 |
| Deferred tax | 10.00 | 107.00 | 59.00 | 21.00 | 7.00 | 8.00 |
| Tax expense | 23.00 | 232.00 | 129.00 | 85.00 | 92.00 | 92.00 |
| Profit for the period | 54.00 | 477.00 | 308.00 | 183.00 | 251.00 | 278.00 |
| Profit attributable to owners | 54.00 | 477.00 | 308.00 | 183.00 | 251.00 | 278.00 |
| Profit attributable to non-controlling interests | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | 5.00 | 96.00 | 2.00 | 4.00 | 2.00 | 20.00 |
| Total comprehensive income | 59.00 | 572.00 | 310.00 | 186.00 | 253.00 | 298.00 |
| Earnings per share, basic | 20.78 | 29.98 | 19.34 | 11.56 | 15.89 | 17.59 |
| Earnings per share, diluted | 20.78 | 29.97 | 19.33 | 11.55 | 15.84 | 17.51 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 4,105.00 | 4,259.00 | 4,470.00 | 4,732.00 | 4,841.00 | 5,032.00 | 5,257.00 | 5,484.00 |
| Non-current assets | 2,190.00 | 2,441.00 | 2,692.00 | 2,952.00 | 3,063.00 | 3,179.00 | 3,318.00 | 3,437.00 |
| Current assets | 1,915.00 | 1,818.00 | 1,778.00 | 1,780.00 | 1,779.00 | 1,853.00 | 1,939.00 | 2,046.00 |
| Property, plant and equipment | 1,758.00 | 1,788.00 | 2,077.00 | 2,478.00 | 2,477.00 | 2,558.00 | 2,590.00 | 3,148.00 |
| Capital work-in-progress | 307.00 | 525.00 | 452.00 | 331.00 | 455.00 | 525.00 | 633.00 | 154.00 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 |
| Other intangible assets | 60.00 | 58.00 | 56.00 | 20.00 | 61.00 | 23.00 | 21.00 | 29.00 |
| Inventories | 1,070.00 | 1,035.00 | 1,050.00 | 941.00 | 889.00 | 943.00 | 928.00 | 880.00 |
| Trade receivables | 527.00 | 511.00 | 454.00 | 572.00 | 591.00 | 607.00 | 760.00 | 783.00 |
| Cash and cash equivalents | 59.00 | 73.00 | 47.00 | 79.00 | 55.00 | 69.00 | 37.00 | 188.00 |
| Total equity and liabilities | 4,105.00 | 4,259.00 | 4,470.00 | 4,732.00 | 4,841.00 | 5,032.00 | 5,257.00 | 5,484.00 |
| Equity | 2,556.00 | 2,666.00 | 2,700.00 | 2,737.00 | 2,815.00 | 2,927.00 | 3,041.00 | 3,126.00 |
| Equity share capital | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 |
| Other equity | 2,540.00 | 2,650.00 | 2,684.00 | 2,722.00 | 2,800.00 | 2,911.00 | 3,025.00 | 3,110.00 |
| Total liabilities | 1,549.00 | 1,593.00 | 1,770.00 | 1,994.00 | 2,026.00 | 2,105.00 | 2,216.00 | 2,358.00 |
| Non-current liabilities | 237.00 | 413.00 | 580.00 | 708.00 | 678.00 | 704.00 | 775.00 | 766.00 |
| Current liabilities | 1,312.00 | 1,180.00 | 1,190.00 | 1,286.00 | 1,348.00 | 1,401.00 | 1,441.00 | 1,592.00 |
| Borrowings, non-current | 0.00 | 150.00 | 300.00 | 426.00 | 386.00 | 368.00 | 365.00 | 330.00 |
| Borrowings, current | 384.00 | 247.00 | 457.00 | 307.00 | 327.00 | 396.00 | 441.00 | 462.00 |
| Trade payables | 738.00 | 801.00 | 589.00 | 767.00 | 824.00 | 815.00 | 814.00 | 941.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 106.00 | 462.00 | 34.00 | 430.00 | 287.00 | 508.00 | 97.00 | 524.00 |
| Net cash from investing activities | -219.00 | -472.00 | -302.00 | -569.00 | -214.00 | -393.00 | -96.00 | -276.00 |
| Net cash from financing activities | 133.00 | 42.00 | 242.00 | 144.00 | -98.00 | -129.00 | -50.00 | -155.00 |
| Purchase of property, plant and equipment | 188.00 | 481.00 | 302.00 | 568.00 | 209.00 | 366.00 | 134.00 | 299.00 |
| Net increase in cash | 21.00 | 35.00 | -26.00 | 6.00 | -24.00 | -9.00 | -33.00 | 119.00 |
| con:CFO.BEFORE_TAX | 146.00 | 540.00 | 66.00 | 476.00 | 335.00 | 588.00 | 158.00 | 628.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 40.00 | 77.00 | 33.00 | 46.00 | 48.00 | 80.00 | 61.00 | 103.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 2.00 | 0.00 | 3.00 | 0.00 | 10.00 | 2.00 | 14.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 0.00 | 0.00 | 2.00 | 1.00 | 14.00 | 3.00 | 10.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 | 11.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 51.47 | 51.47 | 51.47 | 51.47 | 51.47 | 51.47 | 51.47 | 51.47 | 51.47 | 45.22 | 0.45 | 0.45 | 0.45 | 0.45 |
| Domestic institutions | 5.98 | 6.73 | 9.18 | 11.18 | 13.61 | 14.09 | 15.47 | 15.99 | 15.92 | 21.80 | 0.23 | 0.24 | 0.25 | 0.25 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 19.57 | 0.20 | 0.21 | 0.22 | 0.22 |
| Insurance companies | 0.17 | 0.18 | 0.13 | 1.07 | 2.13 | 1.98 | 1.32 | 0.66 | 0.31 | 0.41 | 0.01 | 0.01 | 0.01 | 0.00 |
| Foreign institutions | 7.73 | 6.15 | 6.30 | 6.35 | 6.58 | 6.55 | 7.22 | 6.89 | 7.12 | 6.96 | 0.06 | 0.06 | 0.06 | 0.06 |
| Government | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 48.33 | 47.70 | 47.70 | 47.70 | 47.72 | 47.72 | 47.76 | 47.79 | 47.80 | 54.06 | 0.54 | 0.54 | 0.54 | 0.54 |
| Non-institutional | 34.62 | 34.82 | 32.22 | 30.17 | 27.53 | 27.08 | 25.07 | 24.90 | 24.76 | 25.29 | 0.25 | 0.24 | 0.23 | 0.22 |
| Shares outstanding | 159281139 | 159281139 | 159281139 | 159281139 | 159281139 | 159281139 | 159281139 | 159281139 | 159281139 | 159281139 | 159281139 | 159281139 | 159281139 | 159281139 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Jubilant Life Sciences NV | Subsidiary | Any other transaction, Interest received, Purchase o | 2,982,970,000.00 | 11 |
| Jubilant Infrastructure Limited | Subsidiary | Any other transaction, Interest paid, Purchase of go | 1,402,340,000.00 | 13 |
| Jubilant Life Sciences (USA) Inc. | Subsidiary | Any other transaction, Sale of goods or services | 1,249,190,000.00 | 3 |
| Jubilant Pharmova Limited | Enterprise in which certain direct | Any other transaction, Purchase of goods or services | 280,360,000.00 | 12 |
| Jubilant Life Sciences (Shanghai) Limited | Step-down Subsidiary | Any other transaction, Sale of goods or services | 242,920,000.00 | 2 |
| Jubilant Agri and Consumer Products Limited | Enterprise in which certain direct | Any other transaction, Purchase of goods or services | 230,260,000.00 | 8 |
| Jubilant Agro Sciences Limited | Subsidiary | Any other transaction, Interest received, Investment | 204,440,000.00 | 10 |
| Mr. Deepak Jain | Key management personnel | Remuneration | 139,400,000.00 | 1 |
| Mr. Hari S. Bhartia | Key management personnel | Any other transaction, Remuneration | 93,690,000.00 | 2 |
| Jubilant Ingrevia Employee Welfare Trust | Subsidiary | Any other transaction, Interest paid | 46,830,000.00 | 5 |
| Jubilant Bhartia Foundation | Other related party | Any other transaction, Purchase of goods or services | 46,060,000.00 | 7 |
| AMP Energy Green Fifteen Private Limited | Associates | Any other transaction, Purchase of goods or services | 41,730,000.00 | 2 |
| O2 Renewable Energy XVIII Private Limited | Associates | Investment | 35,870,000.00 | 2 |
| Mr. Prakash Chandra Bisht | Key management personnel | Remuneration | 26,890,000.00 | 1 |
| Jubilant FoodWorks Limited | Enterprise in which certain direct | Any other transaction | 25,430,000.00 | 2 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-07-27 | Q1FY27 | Read the call | |
| 2026-05-29 | Q4FY26 | Read the call | |
| 2026-02-09 | Q3FY26 | Read the call | |
| 2025-10-31 | Q2FY26 | Read the call | |
| 2025-08-06 | Q1FY26 | Read the call | |
| 2025-05-18 | Q4FY25 | Read the call | |
| 2025-03-06 | Q3FY25 | Read the call | |
| 2024-10-28 | Q2FY25 | Read the call | |
| 2024-05-20 | Q4FY24 | Read the call | |
| 2024-02-02 | Q3FY24 | Read the call | |
| 2023-11-06 | Q2FY24 | Read the call | |
| 2023-07-31 | Q1FY24 | Read the call | |
| 2023-05-22 | Q4FY23 | Read the call | |
| 2023-02-04 | Q3FY23 | Read the call | |
| 2022-10-28 | Q2FY23 | Read the call | |
| 2022-08-10 | Q1FY23 | Read the call | |
| 2022-05-21 | Q4FY22 | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | Sir, my question was regarding the CAPEX that we are currently undertaking. | We will consolidate our leadership position there with the new plant, sorry, the new plant will be focusing more on Human Nutrition but even in the An… | So if you just see, Siddharth, we announced a INR2,000 crore capex program 3 years back and all of that capex with this new CDMO plant that we are con… | So, we are not giving the plant wise estimation of capex investment. | Or do we want to bring that down in terms of absolute number revenue of the incremental capex. | And as Deepak mentioned about it that is why we have set up this new plant where we can supply for cosmetic and for food and for sectors where the peo… | First is the overall Rs.2,000 crore CAPEX including some spillover in FY26, what is the kind of revenue you are expecting overall, how much has been a… | In light of that, what is the capex number we should work with for fiscal '27? vi/ JUBILANT INGREVIA |
| Capital allocation | — | We are very clear and in line with the strategy we share today, where we think there are gaps in our portfolio and were doing something inorganically,… | — | — | — | — | — | Just last question on the Nutrition acquisition. |
| Costs | — | Every product, the starting raw material was molasses, it was quite unique from that point of view. | We will, of course, try to do better than that with all the cost-saving initiatives as well as some of the new projects that we are working on. | So, what is the thought process and where we will source the raw materials? | Would that be from the price or would it from the raw material side, what should help from here on to improve this profitability? | — | So, lastly, on that Lean 2.0 where we are expecting Rs.100 crore, Rs.150 crore of incremental cost savings, should we look at that coming entirely in … | When the war began in late February, we saw a sudden escalation in the raw material prices. |
| Debt and cash | — | It will be done through really optimizing our working capital by increasing our credit days and managing our inventory well and the other is releasing… | — | No, you are looking at two numbers INR 800 crore and INR 1,250 crore is the investment number and INR 240 crore, and INR 550 crore are the cash flow n… | — | — | Cash flow is in two forms; one is what we have capitalized; and second is the capital advances which sit in the balance sheet. | — |
| Demand | And with that, the hope is, in the next year or two, it may take a few quarters for demand to come back to the normal levels, but we are hoping that t… | Recently last 6 months or so we accelerated and doubled down on that pipeline. | Number one, I think from a pipeline perspective, we talked about this 100- plus opportunities with a peak potential of about INR3,500 crore. | So, if you recall in the earlier calls also, we have explained that we have a plant of fluorination where we are using HF and we are making the deriva… | To the price reduction, which we have seen, is it more related to demand slowdown? | Just wanted your thoughts on the fact that currently our demand environment is a bit uncertain. | As I shared in the previous two quarters as well, we are going through a down cycle in acetyl business on the acetic anhydride side, at least primaril… | On your broader question on the pipeline of opportunities, these are opportunities which are in different stages. |
| Guidance | Sir, what would the outlook for these new capacities be in the coming years, given the subdued market demand in Specialty and the Chinese dumping that… | We have three main objectives for today, the first is to give you a deeper understanding of all of our business units, the second is to share with you… | Deepak, would appreciate your outlook for how this year is going to end up overall in terms of maybe EBITDA or something and then what you are expecti… | No, once we bring these new capital investments with value added products, we expect specifically in Specialty Chemicals our margins to be improving. | So, since the realization of many of our products, key products has come down, be it Nutrition or Specialty Chemical even Chemical Intermediaries, are… | 1,600 crores revenue number that you talked about, I think we expect our Specialty Chemical business as part of this Pinnacle 345 strategy also. | So, I wanted to understand what are the current spreads in the acetic anhydride business, and also, when can we expect bottoming of both the acetyl cy… | Should we expect any inventory losses beyond 1Q? |
| Margin | On ethyl acetate, from a market perspective, obviously there is some impact on the demand, but from our internal planning purpose, obviously, given th… | Let me also talk about Pinnacle 345, I think the video also explained, what I call the hardware part of it, which is the number - 3x growth, 4 times E… | And you know the EBITDA margins that we have in our Specialty Chemical business. | On this Specialty Chemical business, you mentioned that the volume growth for the year was close to 16%, though the prices have gone up very sharply, … | Or what explains the margin profile in this quarter? | So, I think, Jinal, for the areas where we have put up capacity, most of those are, number one, specialty areas, high-margin products. | The second question is on the spec chem EBITDA for the full year. | I think we have been pretty consistent in saying that if we take our EBITDA, we aspire to get at least 20% year-on-year growth in EBITDA on the full y… |
| People | And most of them are already at 70% plus utilization. | We are hiring the talents in areas where we need to strengthen our capabilities to deliver on the growth vision that we have painted which we will dis… | Secondly, in terms of capacity utilization now from here on beyond the CDMO, can you give some color in terms of capacity utilization or what kind of … | — | So, any number that you can ascribe for the CDMO revenue potential at an optimal utilization, any number that we can work with? | And what you also mentioned is that we're currently operating at 60%, 70% utilization. | And these are the two segments where we have been investing heavily and as we shared in our opening remarks also Rs.1,800 crore of investment that we … | We have capacity of about 50,000 tons for Pyridine and Picoline and we run our plants at 90% plus utilization levels. |
| Pricing | Here, what was the volume decline and how much was led by pricing on the Specialty Chemicals? | Thank you, and the next question is, for the growth roadmap that we have given for Pinnacle 345, is it only the volume growth that we have taken into … | Sir, first question, I think when looking at our comments from the last maybe 2 or 3 quarters, we have been continuously highlighting pricing pressure… | Yes, but it all depends on the market situation also because last year, if you remember, first quarter, we had some positive scenario on pricing. | Very difficult to do the exact percentage, but yes, there has been significant reduction in price realization. | Of course, there is a pricing pressure in some product lines, but I don't think that will change our overall return profile if you look at it from a m… | Specialty segment growth is 15% year-on-year for the whole year FY25 and volume growth is even higher than that because pricing decline in a couple of… | Besides that, a lot depends on what happens to pricing in coming months. |
| Revenue growth | — | So, I am deeply attached to what Jubilant Ingrevia is today because I have seen my own career growth and the growth of Jubilant Ingrevia and really, t… | — | — | Our revenue growth was also coinciding a lot with the disruption, which has happened globally. | — | So, the first question is on FY25 revenue growth. | Secondly, on the CDMO business, so what was our revenue growth in CDMO for FY26? |